Amneal Pharmaceuticals (NYSE:AMRX – Get Free Report) issued an update on its FY 2023 earnings guidance on Friday morning. The company provided EPS guidance of $0.45-$0.55 for the period, compared to the consensus EPS estimate of $0.47. The company issued revenue guidance of $2.30 billion-$2.40 billion, compared to the consensus revenue estimate of $2.32 billion. […]